Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ORTHOCELL LIMITED Director's Dealing 2019

Nov 21, 2019

65477_rns_2019-11-21_8e9cc109-40ac-4d05-9d6d-458c994187c0.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Lars Lidgren
Date of last notice 11 July 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct and Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Algora AB managed by
Banque Carnegie Sweden
(Professor Lidgren is a director of Algora AB)
Date of change 20 November 2019
No. of securities held prior to change
Algora AB Sweden
Managed by Banque Carnegie Sweden with
securites registered as follows:
JP Morgan Nominees Australia Limited
Diamonex Ltd
Algora AB Sweden
365,344 Ordinary Shares
768,091 Ordinary Shares
54,767 Unlisted Warrants exercisable at $0.58 on
or before 19 November 2020
300,000 Unlisted Options exercisable at $0.395
expiring 8 May 2021 (vesting conditions set out
in NOM for General Meeting held on 7 May
2018)
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class Unlisted Options Unlisted Options
Number acquired 500,000
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
Nil
No. of securities held after change
Algora AB Sweden
Managed by Banque Carnegie Sweden with
securites registered as follows:
JP Morgan Nominees Australia Limited
Diamonex Ltd
Algora AB Sweden
365,344 Ordinary Shares
768,091 Ordinary Shares
54,767 Unlisted Warrants exercisable at $0.58
on or before 19 November 2020
300,000 Unlisted Options exercisable at
$0.395 expiring 8 May 2021 (vesting
conditions set out in NOM for General Meeting
held on 7 May 2018)
500,000 Unlisted Options exercisable at
$0.617 expiring 20 November 2022
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Grant of Unlisted Options following
shareholder approval

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.


in thispart.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which interest
related prior to change
Note: Details are only required for a contract in relation to which the interest
has changed
N/A
Interest acquired N/A
  • See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Interest after change N/A

Part 3 Closed Period

art 3 Closed Period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 3